Home » Stocks » CureVac

CureVac N.V. (CVAC)

Stock Price: $52.09 USD -0.81 (-1.53%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 9.27B
Revenue (ttm) 17.38M
Net Income (ttm) -99.87M
Shares Out 177.97M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE 43.67
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $52.09
Previous Close $52.90
Change ($) -0.81
Change (%) -1.53%
Day's Open 52.13
Day's Range 51.66 - 53.28
Day's Volume 470,717
52-Week Range 36.15 - 85.00

More Stats

Market Cap 9.27B
Enterprise Value 9.32B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 177.97M
Float 36.68M
EPS (basic) n/a
EPS (diluted) -0.58
FCF / Share -0.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE 43.67
P/FCF Ratio n/a
PS Ratio 533.42
PB Ratio n/a
Revenue 17.38M
Operating Income -99.50M
Net Income -99.87M
Free Cash Flow -98.14M
Net Cash -47.01M
Net Cash / Share -0.26
Gross Margin n/a
Operating Margin n/a
Profit Margin -573.50%
FCF Margin n/a
ROA -51.16%
ROE n/a
ROIC -91.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$69.01*
(32.49% upside)
Low
58.1
Current: $52.09
High
80.2
Target: 69.01
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue17.4212.87
Revenue Growth35.31%-
Gross Profit-10.57-4.87
Operating Income-99.50-72.82
Net Income-99.87-71.24
Shares Outstanding176-
Earnings Per Share-137.45-98.05
Operating Cash Flow-86.96-74.11
Capital Expenditures-11.17-9.41
Free Cash Flow-98.14-83.52
Cash & Equivalents32.1460.63
Total Debt79.150.08
Net Cash / Debt-47.0160.56
Assets131126
Liabilities17393.58
Book Value-42.8032.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CureVac N.V.
Country Germany
Employees 484
CEO Franz-Werner Haas

Stock Information

Ticker Symbol CVAC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CVAC
IPO Date August 14, 2020

Description

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076